Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402596 | 0.90 | APLNR (0.58) | APLNRTAS1R3TAS1R1LMNACD274 | |
| SCHEMBL29589093 | 0.87 | CD274 (0.61) | APLNRTAS1R3TAS1R1LMNACD274 | |
| SCHEMBL29589384 | 0.87 | CD274 (0.61) | APLNRTAS1R3TAS1R1LMNACD274 | |
| SCHEMBL8803694 | 0.81 | HPGD (0.57) | MAOAMAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL24399602 | 0.81 | APLNR (0.65) | APLNRTAS1R3TAS1R1LMNAMEN1 | |
| SCHEMBL4105525 | 0.81 | APLNR (0.69) | APLNRTAS1R3TAS1R1LMNAMEN1 | |
| SCHEMBL2998236 | 0.80 | APLNR (0.59) | APLNRTAS1R3TAS1R1LMNACD274 | |
| SCHEMBL2248442 | 0.80 | TAS1R3 (0.50) | APLNRTAS1R3TAS1R1LMNACD274 | |
| SCHEMBL14920659 | 0.80 | APLNR (0.49) | APLNRTAS1R3TAS1R1LMNAMEN1 | |
| SCHEMBL3361891 | 0.80 | APLNR (0.63) | APLNRTAS1R3TAS1R1MAOBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2380881-B1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8471038-B2 | Bicyclic heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-2380881-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294804-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | APLNR 1261/4885MAOA 802/4885TAS1R3 1304/4885 |
| US-20130303535-A1 | NOVEL BICYCLIC HETEROCYCLIC COMPOUND | OPRL1, SCN1B, OPRD1 | APLNR 1261/4885MAOA 802/4885TAS1R3 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.